Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Analysis the Positive Rate of Tumor Markers Among Physical Examination Population

6. december 2021 opdateret af: Peking University Third Hospital

Analysis the Positive Status of Tumor Markers Among Physical Examination Population in a Tertiary Grade A Class Hospital

To analyze the positive rate of tumor markers (TM) among health examination population in a tertiary grade A class hospital, compare the differences between different age and sex groups, and explore the possible influencing factors of TM positive.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

From January 2019 to December 2019, who underwent physical examination in Peking University Third Hospital were included in the study. The expression levels of carcinoembryonic antigen (CEA),α-fetoprotein (AFP), carbohydrate antigen 19-9 (CA 19-9), carbohydrate antigen-125 (CA-125), carbohydrate antigen 72-4(CA 72-4), carbohydrate antigen 15-3 (CA 15-3), carbohydrate antigen 242(CA 242), squamous cell carcinoma antigen（SCC）, CYFRA21-1, total prostate-specific antigen (TPSA ) , free prostate-specific antigen(FPSA), neuron specific enolase(NSE) were detected by Electro chemistry luminescence method. The positive rates of TM were analyzed by descriptive statistical method Explore. The differences between different age and sex groups and the influencing factors were explored by statistic by Inferential statistical method.

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

26891

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Kina
      • Beijing, Kina, 100191
        • Peking University Third Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Barn
  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Sandsynlighedsprøve

Studiebefolkning

rom January 2019 to December 2019, who underwent physical examination in Peking University Third Hospital were included in the study.

Beskrivelse

Inclusion Criteria:

  • Those who have taken a physical examination and performed at least one TM test

Exclusion Criteria:

  • Basic information is missing and cannot be retrieved
  • The patient was diagnosed with malignant tumor before examination
  • Those who have not done any TM tests

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
physical examination population
From January 2019 to December 2019, who underwent physical examination in Peking University Third Hospital were included in the study.
Andet: intet indgreb
intet indgreb

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
the positive rate of carcinoembryonic antigen（CEA）
Tidsramme: 2019.01.01-2019.12.31
The proportion of abnormal CEA in physical examination population was calculated. The range of normal value ： CEA≤5 ng/mL.
2019.01.01-2019.12.31
the positive rate of α-fetoprotein（AFP）
Tidsramme: 2019.01.01-2019.12.31
The proportion of abnormal AFP in physical examination population was calculated. The range of normal value ： AFP≤20 ng/mL.
2019.01.01-2019.12.31
the positive rate of carbohydrate antigen 19-9（CA 19-9）
Tidsramme: 2019.01.01-2019.12.31
The proportion of abnormal CA 19-9 in physical examination population was calculated. The range of normal value ： CA 19-9≤39 U/mL.
2019.01.01-2019.12.31
the positive rate of carbohydrate antigen 125（CA 125）
Tidsramme: 2019.01.01-2019.12.31
The proportion of abnormal CA 125 in physical examination population was calculated. The range of normal value ： CA 125≤35 U/mL.
2019.01.01-2019.12.31
the positive rate of carbohydrate antigen 72-4（CA 72-4）
Tidsramme: 2019.01.01-2019.12.31
The proportion of abnormal CA 72-4 in physical examination population was calculated. The range of normal value ： CA 72-4≤8.2 U/mL.
2019.01.01-2019.12.31
the positive rate of carbohydrate antigen 15-3（CA 15-3）
Tidsramme: 2019.01.01-2019.12.31
The proportion of abnormal CA 15-3 in physical examination population was calculated. The range of normal value ： CA 15-3≤25 IU/mL.
2019.01.01-2019.12.31
the positive rate of carbohydrate antigen 242（CA 242）
Tidsramme: 2019.01.01-2019.12.31
The proportion of abnormal CA 242 in physical examination population was calculated. The range of normal value ：CA 242≤20 U/mL.
2019.01.01-2019.12.31
the positive rate of squamous cell carcinoma antigen（SCC）
Tidsramme: 2019.01.01-2019.12.31
The proportion of abnormal SCC in physical examination population was calculated. The range of normal value ：SCC≤1.5 ng/mL.
2019.01.01-2019.12.31
the positive rate of Cytokeratin 19 fragment 21-1（CYFRA21-1）
Tidsramme: 2019.01.01-2019.12.31
The proportion of abnormal CYFRA21-1 in physical examination population was calculated. The range of normal value ：CYFRA21-1≤3.3 ng/mL.
2019.01.01-2019.12.31
the positive rate of total prostate-specific antigen（ TPSA）
Tidsramme: 2019.01.01-2019.12.31
The proportion of abnormal TPSA in physical examination population was calculated. The range of normal value ：TPSA≤4 ng/mL.
2019.01.01-2019.12.31
the positive rate of free prostate-specific antigen（ FPSA）
Tidsramme: 2019.01.01-2019.12.31
The proportion of abnormal FPSA in physical examination population was calculated. The range of normal value ：FPSA≤1 ng/mL.
2019.01.01-2019.12.31
the positive rate of neuron specific enolase（ NSE）
Tidsramme: 2019.01.01-2019.12.31
The proportion of abnormal NSE in physical examination population was calculated. The range of normal value ：NSE≤17 ng/mL.
2019.01.01-2019.12.31

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
age
Tidsramme: 2019.01.01-2019.12.31
the age of physical examination population.
2019.01.01-2019.12.31
the measured value of systolic blood pressure (SBP)
Tidsramme: 2019.01.01-2019.12.31
SBP measured on the day of physical examination.Unit of measure：mmHg
2019.01.01-2019.12.31
the measured value of diastolic blood pressure (DBP)
Tidsramme: 2019.01.01-2019.12.31
DBP measured on the day of physical examination.Unit of measure：mmHg
2019.01.01-2019.12.31
the measured value of fasting bood glucose (FBG)
Tidsramme: 2019.01.01-2019.12.31
FBG measured on the day of physical examination.Unit of measure：mmol/L
2019.01.01-2019.12.31
the measured value of total cholesterol (TC)
Tidsramme: 2019.01.01-2019.12.31
TC measured on the day of physical examination.Unit of measure：mmol/L
2019.01.01-2019.12.31
the measured value of Triglyceride (TG)
Tidsramme: 2019.01.01-2019.12.31
TG measured on the day of physical examination.Unit of measure：mmol/L
2019.01.01-2019.12.31
the measured value of high density lipoprotein-cholesterol (HDL-C)
Tidsramme: 2019.01.01-2019.12.31
HDL-C measured on the day of physical examination.Unit of measure：mmol/L
2019.01.01-2019.12.31
the measured value of low density lipoprotein-cholesterol (LDL-C)
Tidsramme: 2019.01.01-2019.12.31
LDL-C measured on the day of physical examination.Unit of measure：mmol/L
2019.01.01-2019.12.31
the measured value of height
Tidsramme: 2019.01.01-2019.12.31
height measured on the day of physical examination.Unit of measure：cm
2019.01.01-2019.12.31
the measured value of weight
Tidsramme: 2019.01.01-2019.12.31
height measured on the day of physical examination.Unit of measure：kg
2019.01.01-2019.12.31
Body Mass Index (BMI)
Tidsramme: 2019.01.01-2019.12.31
weight and height will be combined to report BMI in kg/m^2
2019.01.01-2019.12.31

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Peking University Third Hospital

Efterforskere

  • Studieleder: Wei Zhao, doctorate, Peking University Third Hospital

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. januar 2019

Primær færdiggørelse (Faktiske)

31. december 2019

Studieafslutning (Faktiske)

31. december 2019

Datoer for studieregistrering

Først indsendt

20. oktober 2021

Først indsendt, der opfyldte QC-kriterier

6. december 2021

Først opslået (Faktiske)

21. december 2021

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

21. december 2021

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

6. december 2021

Sidst verificeret

1. september 2021

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • IRB00006761-M2021321

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

no share

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Svulst

Kliniske forsøg med intet indgreb

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Paraguay

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

3
Abonner